Quince Therapeutics Inc (QNCX): Price/Earnings to Growth Multiple

Symbol and logo of brand Quince (QNCX)

The current PEG ratio helps assess the efficiency of Quince Therapeutics' robotic drug synthesis. The model relies on production outsourcing to minimize costs and the stability of the US development environment. The value of 0.00 reflects the metric's baseline, allowing for the rapid identification of undervalued assets and a real-time assessment of the business's fundamental margin of safety.

QNCX Quince Therapeutics Price/Earnings to Growth Multiple (04/28/2023 - 10/12/2026)

Analytical breakdowns for Quince Therapeutics, Inc. (QNCX)

- share price and consensus valuation forecast:
- stock exchange capitalization data:
Fundamental company analysis:QNCX - Quince Therapeutics
Signature product of quincetx.com

Quince Therapeutics focuses on developing metabolic drugs with minimal environmental impact. The specifics of the biotechnology sector make the PEG ratio a key tool for comparing current market capitalization with earnings growth. This metric divides the P/E ratio by the business growth rate, revealing the real value of the company's expansion. A value below one signals that assets are undervalued. Analysis using the PEG ratio helps determine a fair balance between price and investment risk.

Competitors of Quince Therapeutics

ASND (Ascendis) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio madrigalpharma.com MDGL|CORT - Price/Earnings to Growth Multiple|Rhythm Corp - PEG Multiple|Price to Earnings Adjusted for Growth Rate Akero Therapeutics Inc|MTSR (Metsera) - Price/Earnings to Growth Multiple|MLTX: Company Value to Earnings Growth Ratio|CRNX (Crinetics Corp) - PEG Multiple|PEG Multiple NewAmsterdam Pharma|PEG Multiple SLNO|Price/Earnings to Growth Ratio FOLD (Amicus Therapeutics Inc)|Price/Earnings to Growth Ratio 89bio.com ETNB|Agios Corp (AGIO) - Price to Earnings Adjusted for Growth Rate|GPCR - Price/Earnings to Growth Ratio|MDXG: Price/Earnings to Growth Ratio|RZLT: PEG Multiple|LXRX - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio MBX Corp|Price/Earnings to Growth Multiple Altimmune Corp (ALT)|Price/Earnings to Growth Ratio aardvarktherapeutics.com (AARD)|Price/Earnings to Growth Multiple sagimet.com SGMT|PEG Multiple BIOA (BioAge)|Biomea Fusion - Price/Earnings to Growth Ratio|GUTS - Price/Earnings to Growth Ratio|vTv Therapeutics, Inc. - Company Value to Earnings Growth Ratio|ATPC: PEG Multiple|Pluri Inc (PLUR) - PEG Multiple|Price/Earnings to Growth Ratio Synlogic, Inc.|Price to Earnings Adjusted for Growth Rate Lipocine LPCN|Price/Earnings to Growth Ratio Matinas BioPharma Holdings Inc. (MTNB)|Price/Earnings to Growth Multiple Spruce Biosciences SPRB|Galecto Corp - Price/Earnings to Growth Multiple|carmellrx.com - Price/Earnings to Growth Ratio|LUMO - Price/Earnings to Growth Ratio|ONVO: Price/Earnings to Growth Ratio|Radius Health (RDUS) - Price/Earnings to Growth Ratio